New combo therapy aims to eliminate rectal tumors without surgery

NCT ID NCT07150949

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times

Summary

This study tests two different treatment plans for people with locally advanced rectal cancer that hasn't spread. One group gets standard long-course chemoradiation followed by chemo. The other gets short-course radiation followed by chemo, an immunotherapy drug (PD-1 antibody), and an anti-inflammatory drug (COX-2 inhibitor). The goal is to see which approach leads to a complete disappearance of the cancer, possibly avoiding the need for surgery. The trial involves 138 adults with a specific type of rectal cancer (MSS/pMMR).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.